Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16884220 | 0.79 | HDAC6 (0.52) | HDAC6HDAC3HDAC1MEN1KMT2A | |
| SCHEMBL20535519 | 0.74 | HDAC6 (0.48) | HDAC6HDAC3HDAC1HDAC2P2RX7 | |
| SCHEMBL18088397 | 0.74 | HDAC6 (0.61) | HDAC6HDAC3HDAC1HDAC2P2RX7 | |
| SCHEMBL10067533 | 0.73 | P2RX7 (0.67) | HDAC6HDAC3HDAC1HDAC2P2RX7 | |
| SCHEMBL13927593 | 0.71 | KCNH2 (0.44) | HDAC6HDAC3HDAC1MEN1KMT2A | |
| SCHEMBL1347586 | 0.71 | KDM1A (0.51) | HDAC6HDAC3HDAC1HDAC2P2RX7 | |
| SCHEMBL18085885 | 0.71 | HDAC6 (0.57) | HDAC6HDAC3HDAC1HDAC2P2RX7 | |
| SCHEMBL20535185 | 0.70 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2P2RX7 | |
| SCHEMBL7662002 | 0.70 | CYP11B1 (0.40) | — | |
| SCHEMBL9080180 | 0.69 | HDAC6 (0.54) | HDAC6HDAC3HDAC1HDAC2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2018191587-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | PIK3CA, MAP3K1, MAP3K5 | HDAC6 1041/4885HDAC3 609/4885HDAC1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.